Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 139-145

  Beerepoot, L V ^a   Mehra, N ^a   Vermaat, J S P ^a   Zonnenberg, B A ^a   Gebbink, M F G B ^a   Voest, E E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Cancer; Circulating endothelial cells

Indexed keywords

CALCEIN; CD31 ANTIGEN; CELL MARKER; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLACENTA PROTEIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CELL COUNT; CELL ISOLATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; CYTOKINES; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 0942277099     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh017     Document Type: Article

References (48)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Carmeliet P, Luttun A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb Haemost 2001; 86: 289-297.
3. Rafii S, Lyden D, Benezra R et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835.
4. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovasculatization. Circ Res 1999; 85: 221-228.
5. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
6. Mutin M, Canavy I, Blann A et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951-2958.
7. George F, Brouqui P, Boffa MC et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 1993; 82: 2109-2116.
8. Woywodt A, Streiber F, De Groot K et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361: 206-210.
9. Solovey A, Lin Y, Browne P et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-1590.
10. Popa ER, Kas-Deelen AM, Hepkema BG et al. Donor-derived circulating endothelial cells after kidney transplantation. Transplantation 2002; 74: 1320-1327.
11. Gill M, Dias S, Hattori K et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001; 88: 167-174.
12. Kalka C, Tehrani H, Laudenberg B et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000; 70: 829-834.
13. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-2890.
14. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
15. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7.
16. Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
17. Mancuso P, Burlini A, Pruneri G et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661.
18. Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002; 9: 631-641.
19. Chang YS, di Tomaso E, McDonald DM et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97: 14608-14613.
20. George F, Brisson C, Poncelet P et al. Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992; 67: 147-153.
21. George F, Poncelet P, Laurent JC et al. Cytofluorometric detection of human endothelial cells in whole blood using S-Endo 1 monoclonal antibody. J Immunol Methods 1991; 139: 65-75.
22. Bardin N, Anfosso F, Masse JM et al. Identification of CD 146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98: 3677-3684.
23. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 1990; 133: 87-97.
24. Dumitriu IE, Mohr W, Kolowos W et al. 5,6-Carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. Anal Biochem 2001; 299: 247-252.
25. Ades EW, Candal FJ, Swerlick RA et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
26. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
27. Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000; 105: 1527-1536.
28. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "Endothelial Progenitor Cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
29. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
30. Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
31. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427.
32. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436.
33. Davidoff AM, Ng CY, Brown P et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7: 2870-2879.
34. de Bont ES, Guikema JE, Scherpen F et al. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res 2001; 61: 7654-7659.
35. Ojeifo JO, Lee HR, Rezza P et al. Endothelial cell-based systemic gene therapy of metastatic melanoma. Cancer Gene Ther 2001; 8: 636-648.
36. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
37. Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45-46.
38. Tse HF, Kwong YL, Chan JK et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-49.
39. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
40. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
41. Lambeir AM, Proost P, Durinx C et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276: 29839-29845.
42. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
43. Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001; 19: 37-45.
44. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104: 121-129.
45. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80 (Suppl 1): 57-64.
46. Radema SA, Beerepoot LV, Witteveen PO et al. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 2002; 21 (Abstr 439).
47. Natori T, Sata M, Washida M et al. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2002; 297: 1058.
48. Shi Q, Bhattacharya V, Hong-De Wu M, Sauvage LR. Utilizing granulocyte colony-stimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann Vasc Surg 2002; 16: 314-320.